PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10489905-5 1999 Infusion of atropine (10(-6) M) had no effect on the SP-induced GLP-1 release, but partly inhibited the effect of SP on somatostatin and VIP release, and the effect of NKA on VIP release. Atropine 12-20 tachykinin precursor 1 Homo sapiens 114-116 10489905-5 1999 Infusion of atropine (10(-6) M) had no effect on the SP-induced GLP-1 release, but partly inhibited the effect of SP on somatostatin and VIP release, and the effect of NKA on VIP release. Atropine 12-20 tachykinin precursor 1 Homo sapiens 168-171 9543242-7 1998 Atropine had no effect on tracheal contractions to neurokinin A and substance P, while [Sar9, Met(O2)11]substance P contractions were atropine sensitive. Atropine 134-142 tachykinin precursor 1 Homo sapiens 104-115 8683731-4 1996 RESULTS: Substance P and BK potentiated responses to the purinergic component of the neurogenic stimulation (that part of the contractile response that remains after treatment with atropine) and potentiated responses to exogenously applied adenosine triphosphate (ATP). Atropine 181-189 tachykinin precursor 1 Homo sapiens 9-20 8878063-20 1996 We conclude that endogenous tachykinins are involved in mediating atropine-resistant reflex contractions evoked by distension of the rat duodenum in vivo: both NK1 and NK2 receptors are activated by endogenous ligands to produce NANC contractions of rat duodenum in vivo. Atropine 66-74 tachykinin precursor 1 Homo sapiens 168-171 2476938-6 1989 Both atropine and tetrodotoxin reduced the response of substance P at the ileal site. Atropine 5-13 tachykinin precursor 1 Homo sapiens 55-66 1376358-6 1992 SP activity was significantly reduced in tissues pretreated with the muscarinic cholinoceptor blocker atropine or the eicosanoid synthesis inhibitor eicosa-5,8,11,14-tetraynoic acid. Atropine 102-110 tachykinin precursor 1 Homo sapiens 0-2 1376358-8 1992 SP-induced contractions were reduced by 70 to 80% in tissues pretreated with atropine or the neuronal Ca++ channel blocker, omega-conotoxin. Atropine 77-85 tachykinin precursor 1 Homo sapiens 0-2 1373711-7 1992 Atropine (2 mg/kg) significantly diminished the responses of tracheal tension to SP and NKA, indicating a cholinergic contribution to these responses at all ages. Atropine 0-8 tachykinin precursor 1 Homo sapiens 81-83 1373711-7 1992 Atropine (2 mg/kg) significantly diminished the responses of tracheal tension to SP and NKA, indicating a cholinergic contribution to these responses at all ages. Atropine 0-8 tachykinin precursor 1 Homo sapiens 88-91 1377730-5 1992 Also acetylcholine infusion causes a significant release of SP and NKA after infusion of both atropine and phentolamine (to 172 +/- 56% and 232 +/- 69% of basal release, n = 7), an effect that was abolished by hexamethonium infusion. Atropine 94-102 tachykinin precursor 1 Homo sapiens 60-62 1377730-5 1992 Also acetylcholine infusion causes a significant release of SP and NKA after infusion of both atropine and phentolamine (to 172 +/- 56% and 232 +/- 69% of basal release, n = 7), an effect that was abolished by hexamethonium infusion. Atropine 94-102 tachykinin precursor 1 Homo sapiens 67-70 1377730-6 1992 Infusion of atropine alone increased the release of SP and NKA significantly (to 337 +/- 92% and 386 +/- 124% of basal output, n = 5). Atropine 12-20 tachykinin precursor 1 Homo sapiens 52-54 1377730-6 1992 Infusion of atropine alone increased the release of SP and NKA significantly (to 337 +/- 92% and 386 +/- 124% of basal output, n = 5). Atropine 12-20 tachykinin precursor 1 Homo sapiens 59-62 2472555-2 1989 When the tone was raised by addition of galanin (0.3-1 microM), prostaglandin (PG) E2 (1-10 microM) or neurokinin A (NKA, 0.1 microM), a frequency-related relaxation was evident which was potentiated by atropine. Atropine 203-211 tachykinin precursor 1 Homo sapiens 103-115 2470258-7 1989 Substance P- but not CCK-8- or neurotensin-induced contractions of gastric muscle were reduced by tetrodotoxin (TTX) and atropine (P less than 0.05). Atropine 121-129 tachykinin precursor 1 Homo sapiens 0-11 2470273-6 1989 Substance P induced atropine-resistant nasal secretion in a dose-dependent manner in anaesthetized dogs and rats. Atropine 20-28 tachykinin precursor 1 Homo sapiens 0-11 2469860-6 1989 Administration of the antimuscarinic drug atropine only slightly affected the SO spikeburst frequency when infused prior to SP (73.0 +/- 10.4 vs 70.8 +/- 8.2, P greater than 0.05). Atropine 42-50 tachykinin precursor 1 Homo sapiens 124-126 2462362-6 1988 In longitudinal muscle treated with atropine and in circular muscle, the rank order of potency for the inotropic response was NKA greater than NKB greater than SP greater than SPME. Atropine 36-44 tachykinin precursor 1 Homo sapiens 126-129 669213-7 1978 Atropine in 40-, 250-, and 500-microgram per kg doses significantly but partially inhibited the response of the LES to substance P. Atropine 0-8 tachykinin precursor 1 Homo sapiens 119-130 2443476-3 1987 SP-induced contraction is blocked completely by atropine and augmented by neostigmine. Atropine 48-56 tachykinin precursor 1 Homo sapiens 0-2 2437874-2 1987 It also responded to exogenous substance P by an atropine-insensitive mechanism. Atropine 49-57 tachykinin precursor 1 Homo sapiens 31-42 6166979-6 1981 VIP and SP are potant mediators of atropine resistent vasodilatation in the mucosa. Atropine 35-43 tachykinin precursor 1 Homo sapiens 8-10 3475146-4 1987 Plasma protein extravasation induced by SP (66 pmol) was significantly reduced (63%; P less than 0.001) by atropine (a muscarinic inhibitor) while that induced by NKA or NKB was unaffected by the inhibitor suggesting that a cholinergic component might only be involved in the vascular permeability elicited by SP. Atropine 107-115 tachykinin precursor 1 Homo sapiens 40-42 3475146-4 1987 Plasma protein extravasation induced by SP (66 pmol) was significantly reduced (63%; P less than 0.001) by atropine (a muscarinic inhibitor) while that induced by NKA or NKB was unaffected by the inhibitor suggesting that a cholinergic component might only be involved in the vascular permeability elicited by SP. Atropine 107-115 tachykinin precursor 1 Homo sapiens 310-312 6196939-2 1983 The substance P-induced contractions were resistant to mepyramine and atropine, suggesting a direct effect on the bronchial smooth muscle. Atropine 70-78 tachykinin precursor 1 Homo sapiens 4-15 6196809-4 1983 The contractile effects of SP were sensitive to atropine or local infusion of a SP analogue, (D-Pro2,D-Trp7,9)-SP, indicating that SP activated a final common cholinergic neuron in both stomach and pylorus. Atropine 48-56 tachykinin precursor 1 Homo sapiens 27-29 6196809-9 1983 injection of SP, was sensitive to atropine or the SP analogue but hexamethonium resistant. Atropine 34-42 tachykinin precursor 1 Homo sapiens 13-15 6163321-0 1980 Atropine sensitive contractile motor effects of substance P on the feline pylorus and stomach in vivo. Atropine 0-8 tachykinin precursor 1 Homo sapiens 48-59 34866-5 1979 The secreto-vasomotor responses can be influenced by activation of these fibres and the atropine resistant vasodilatation seen following Vidian nerve stimulation thus may partly be due to activation and release of SP and VIP. Atropine 88-96 tachykinin precursor 1 Homo sapiens 214-216 620895-4 1978 Unlike the gastrin peptide analogue caerulein, the effects of which were mediated through the release of acetylcholine from the enteric plexuses, the site of action of substance P appeared to be directly on the muscle cells because its effects were resistant to atropine, tetrodotoxin, and Lioresal. Atropine 262-270 tachykinin precursor 1 Homo sapiens 168-179